Breast cancer drug Herceptin approved in Europe
Filed under: Breast Cancer, Drug, Clinical Trials, Research, Daily news
Breast cancer drug Herceptin has been approved in Europe for use with hormonal therapy for postmenopausal patients with HER2 and hormone receptor positive metastatic disease.
Herceptin, made by Swiss drugmaker Roche Holding AG, is already approved in Europe for early and metastatic HER2-positive breast cancer.
This new approval is based on data from an international late stage clinical trial showing the combination of Herceptin with hormonal therapy doubled the median progression-free survival time.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Jacki Donaldson
No comments yet. Be the first.
Leave a reply
Breast cancer drug Herceptin approved in Europe
Filed under: Breast Cancer, Drug, Clinical Trials, Research, Daily news
Breast cancer drug Herceptin has been approved in Europe for use with hormonal therapy for postmenopausal patients with HER2 and hormone receptor positive metastatic disease.
Herceptin, made by Swiss drugmaker Roche Holding AG, is already approved in Europe for early and metastatic HER2-positive breast cancer.
This new approval is based on data from an international late stage clinical trial showing the combination of Herceptin with hormonal therapy doubled the median progression-free survival time.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Jacki Donaldson
No comments yet. Be the first.
Leave a reply